RxDoctor Payments DataLook up a doctor →

Thomas Kaelin, DO

Pulmonary Disease · N Charleston, SCNPI 1740280841

Payments from drug & device makers

$1,755,037in general payments, 2019–2025

Across 889 payments — averaging $1974.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$528K
  • AstraZeneca$224K
  • Roche Products Limited$166K
  • Harmony Biosciences LLC$139K
  • GSK$121K
  • Merck$113K
  • plus $464K from 52 others
$1,814in research payments, 2019–2025

Across 15 payments — averaging $120.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$2K

What the payments were for

  • Consulting fees$11,71134%
  • Speaking & faculty fees$8,63325%
  • Travel & lodging$3,0419%
  • Food & beverage$11,11832%
  • Education$1961%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim131$527,559
AstraZeneca90$224,149
Roche Products Limited23$166,430
Harmony Biosciences LLC66$139,126
GSK76$120,627
Merck39$113,336
Genentech, Inc.10$103,110
Mylan Specialty L.p.32$82,138
Sanofi US Services Inc.21$76,605
Boehringer Ingelheim International GmbH103$53,919
Verona Pharma, Inc.4$39,248
Teva Pharmaceuticals USA, Inc.27$28,621
Astrazeneca UK Limited13$26,851
Chiesi USA, Inc.6$19,292
Hoffmann-la Roche Limited3$17,361
Novartis3$9,300
Jazz Pharmaceuticals Inc.44$1,570
Boehringer Ingelheim Pharma GmbH & Co.kg1$898
Axsome Therapeutics, Inc.22$588
Avadel CNS Pharmaceuticals, LLC12$489
Mallinckrodt Hospital Products Inc.19$433
Regeneron Healthcare Solutions, Inc.13$403
Takeda Pharmaceuticals U.S.A., Inc.15$342
Sanofi11$245
United Therapeutics Corporation8$199
Grifols USA, LLC10$185
Inari Medical, Inc.1$175
Insmed, Inc.7$175
Genentech USA, Inc.8$174
Vanda Pharmaceuticals Inc.5$152
CSL Behring5$142
Sunovion Pharmaceuticals Inc.9$121
Actelion Pharmaceuticals US, Inc.6$114
Inspire Medical Systems, Inc.2$109
Gilead4$78
Amgen3$77
Pharming Healthcare, Inc.3$66
Idorsia Pharmaceuticals US Inc4$63
ANI Pharmaceuticals, Inc.3$57
Resmed Corp3$52
Shire North American Group Inc3$48
Astellas Pharma US Inc2$39
Inogen, Inc.1$35
Pfizer2$35
Optinose US, Inc.2$31
Philips North America LLC1$31
Electromed, Inc.2$30
Vapotherm Inc1$24
Itamar Medical Inc1$23
Lilly USA, LLC1$22
Apria Healthcare LLC1$22
Johnson & Johnson1$20
Advanced Respiratory, Inc1$19
Nabriva Therapeutics, PLC1$19
Paratek Pharmaceuticals, Inc.1$18
Circassia Inc.1$17
AbbVie1$14
Almatica Pharma LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,755,037 in reported general payments places this provider in the 90th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$323,947
Medicare patients
1,664
Services billed
3,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter128$111,533
Breo ElliptaFluticasone/Vilanterol38$19,858
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,988
Tiotropium Bromide11$4,671
Albuterol Sulfate HfaAlbuterol Sulfate128$4,523
SymbicortBudesonide/Formoterol Fumarate15$4,278
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,167
Wixela InhubFluticasone Propion/Salmeterol16$1,832
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$809
Azithromycin21$365
Prednisone41$246
Montelukast Sodium11$130
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$129
Eszopiclone14$110
Lorazepam13$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$120,627$131,391166 claims
Boehringer IngelheimStiolto Respimat$527,559$5,98811 claims
AstraZenecaSymbicort$224,149$4,27815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 192 pulmonary disease providers in South Carolina.

Other pulmonary disease in N Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →